Eli Lilly's weight loss drug Zepbound and diabetes treatment Mounjaro experienced weaker-than-expected sales in the third quarter, attributed to wholesalers reducing inventory rather than a decline in demand. Mounjaro's sales reached $3.11 billion, falling short of the $3.7 billion forecast, while Zepbound generated $1.26 billion, missing the $1.76 billion expectation. Despite strong underlying demand, Eli Lilly plans to initiate promotional activities for Zepbound in November to boost sales.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
